Related references
Note: Only part of the references are listed.Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia
Franco Locatelli et al.
PEDIATRIC BLOOD & CANCER (2022)
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
Nicholas J. Short et al.
BLOOD ADVANCES (2022)
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside
Xinyue Deng et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Emily C. Liang et al.
BLOOD (2022)
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Mark R. Litzow et al.
BLOOD (2022)
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
Anne Tierens et al.
CURRENT ONCOLOGY (2021)
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL
Michaela Kotrova et al.
BLOOD (2015)
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
Michael A. Pulsipher et al.
BLOOD (2015)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)